Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT04764227
PHASE2
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
Sponsor: Fudan University
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate safety and 2-year local control rate for postoperative concurrent chemoradiotherapy for esophageal squamous cell carcinoma.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2020-05-30
Completion Date
2027-03-30
Last Updated
2023-08-03
Healthy Volunteers
No
Conditions
Interventions
DRUG
Paclitaxel
paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
DRUG
Carboplatin
carboplatin AUC=2, ivgtt, d1, qw\*5
RADIATION
Radiotherapy
1.8Gy/d, d1-5/week, 28Fx
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, China